At the end of the latest market close, Reata Pharmaceuticals Inc. (RETA) was valued at $26.73. In that particular session, Stock kicked-off at the price of $26.82 while reaching the peak value of $26.9366 and lowest value recorded on the day was $24.60. The stock current value is $24.72.Recently in News on September 6, 2022, Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference. Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in investor meetings at the Citi 17th Annual BioPharma Conference on September 7 – 8, 2022 in Boston, Massachusetts. You can read further details here
Reata Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $40.64 on 03/23/22, with the lowest value was $18.47 for the same time period, recorded on 08/17/22.
Reata Pharmaceuticals Inc. (RETA) full year performance was -76.85%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Reata Pharmaceuticals Inc. shares are logging -78.47% during the 52-week period from high price, and 33.84% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $18.47 and $114.80.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 719063 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Reata Pharmaceuticals Inc. (RETA) recorded performance in the market was -6.26%, having the revenues showcasing -23.61% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 943.32M, as it employees total of 346 workers.
Reata Pharmaceuticals Inc. (RETA) in the eye of market guru’s
During the last month, 6 analysts gave the Reata Pharmaceuticals Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 28.45, with a change in the price was noted -1.69. In a similar fashion, Reata Pharmaceuticals Inc. posted a movement of -6.40% for the period of last 100 days, recording 660,291 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for RETA is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Reata Pharmaceuticals Inc. (RETA): Stocks Technical analysis and Trends
Raw Stochastic average of Reata Pharmaceuticals Inc. in the period of last 50 days is set at 33.88%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 34.28%. In the last 20 days, the company’s Stochastic %K was 55.46% and its Stochastic %D was recorded 66.60%.
If we look into the earlier routines of Reata Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -6.26%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -37.58%, alongside a downfall of -76.85% for the period of the last 12 months. The shares increased approximately by -14.49% in the 7-day charts and went down by 16.66% in the period of the last 30 days. Common stock shares were lifted by -23.61% during last recorded quarter.